Faget Comments on Likely Effects of HHS Proposal to Curb Rebates
February 20, 2019
BioPharm Insight
Special Counsel Kyle Faget is quoted in a BioPharm Insight article, “Biosimilars, diabetes and HCV drug uptake expected to spike with HHS changes restricting safe harbor protection for PBMs and drug manufacturers, experts say,” about the expected impact of a new U.S. Department of Health and Human Services proposal to exclude rebates on prescription drugs from safe harbor protection under the anti-kickback statute.
Faget said an obstacle to automatic biosimilar uptake under the proposal may be that as opposed to generics, pharmacists cannot automatically switch out an originator for a biosimilar, unless interchangeability has been established by the biosimilar maker. She cited the example of Pfizer’s Ixifi, which can’t be substituted for Remicade by a pharmacist even if it’s cheaper. Remicade is approved to treat a number of indications, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and ankylosing spondylitis.
(Subscription Required)
Faget said an obstacle to automatic biosimilar uptake under the proposal may be that as opposed to generics, pharmacists cannot automatically switch out an originator for a biosimilar, unless interchangeability has been established by the biosimilar maker. She cited the example of Pfizer’s Ixifi, which can’t be substituted for Remicade by a pharmacist even if it’s cheaper. Remicade is approved to treat a number of indications, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and ankylosing spondylitis.
(Subscription Required)
People
Related News
July 2, 2025
In the News
John Strom and Peter Tomasi Quoted on Shift in Environmental Policy
Foley & Lardner LLP attorneys John Strom and Peter Tomasi commented on changes to federal environmental rules in the Utility Dive article, "Federal agencies, including FERC and DOE, revoke environmental review rules."
June 30, 2025
In the News
Lynn Gandhi Assesses Midyear Takeaways from Major State and Local Tax Cases
Foley & Lardner LLP partner Lynn Gandhi is featured by Law360 for her takeaways on major state and local tax cases in the article, "Top State & Local Tax Cases Of 2025: Midyear Report."
June 27, 2025
In the News
Donald Schroeder Highlights FMCS Importance Amid Service's Uncertain Future
Foley & Lardner LLP partner Donald Schroeder described the Federal Mediation and Conciliation Services' (FMCS) importance in the Law360 article, "As Feds' Bargaining Mediator Ails, New Services Emerge."